research use only
Cat.No.S3810
| Related Targets | EGFR JAK Pim |
|---|---|
| Other STAT Inhibitors | Napabucasin (BBI608) Stattic NSC 74859 (S3I-201) Cryptotanshinone (Tanshinone C) C188-9 (TTI-101) SH-4-54 BP-1-102 AS1517499 Nifuroxazide HO-3867 |
|
In vitro |
DMSO
: 50 mg/mL
(108.14 mM)
Water : 2 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 462.36 | Formula | C21H18O12 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 27740-01-8 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | Breviscapine, Breviscapin, Scutellarein-7-glucuronide | Smiles | C1=CC(=CC=C1C2=CC(=O)C3=C(C(=C(C=C3O2)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)O)O | ||
| Targets/IC50/Ki |
STAT3
Akt
NF-κB
|
|---|---|
| In vitro |
Scutellarin protects PC12 cells against H2O2-induced cytotoxicity. It attenuates H2O2-induced intracellular accumulation of ROS and lipid peroxidation. This compound shows negligible inhibitory effects on the six major CYP isoenzymes in human/rat liver microsomes with almost all of the IC50 values exceeding 100 μM, whereas it shows values of 63.8 μM for CYP2C19 in human liver microsomes, and 63.1 and 85.6 μM for CYP2C7 and CYP2C79 in rat liver microsomes, respectively. It also has weak inhibitory effect on P-gp. This chemical strongly induces MMP-2 activation and mRNA expression in cultured HUVECs in a concentration-dependent manner. It promotes angiogenesis and may form a basis for angiogenic therapy. |
| In vivo |
The pharmacokinetic results indicate that scutellarin undergoes rapid and extensive biotransformation in vivo. After intraperitoneal injection. this compound is absorbed rapidly. The relative bioavailability of oral administration is very low (10.67 %±4.78 %). It has a series of protective effects including dilate blood vessels, improving microcirculation, decreasing the viscosity of blood, reducing the blood platelet count, inhibiting platelet aggregation activity etc. |
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT02559960 | Suspended | Adverse Drug Event|Adverse Drug Reaction|Chinese Medicine|Anaphylactic Reaction |
Zhong Wang|China Academy of Chinese Medical Sciences |
September 2015 | -- |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.